Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Natalizumab
87%
Asthma
72%
Clinical Trial
52%
Progressive Multifocal Leukoencephalopathy
32%
Crohn's Disease
27%
Recurrence Risk
23%
Adverse Event
23%
Spasticity
14%
Fingolimod
14%
Rituximab
14%
Laquinimod
14%
Cladribine
14%
Alemtuzumab
14%
Daclizumab
14%
Teriflunomide
14%
4-Aminopyridine
14%
Fumaric Acid
14%
Gadolinium
14%
Phase II Trials
14%
Inflammatory Disease
14%
Pathophysiology
14%
Glatiramer
9%
Beta1a Interferon
9%
Immunosuppressive Agent
9%
Monoclonal Antibody
9%
Monotherapy
9%
Inflammation
9%
Neuroscience
Multiple Sclerosis
90%
Natalizumab
87%
Progressive Multifocal Leukoencephalopathy
32%
Adverse Effect
23%
Daclizumab
14%
Alemtuzumab
14%
Antigen Antibody Complex
14%
Rituximab
14%
Teriflunomide
14%
Cladribine
14%
Vigilance
14%
Central Nervous System
14%
Clinical Assessment
14%
Glatiramer Acetate
9%
Interferon Beta 1a
9%
Rebound Effect
9%
Antibody Production
9%
Monoclonal Antibody
9%
Treatment of Multiple Sclerosis
9%
Immunosuppressive Drug
9%
Leukocyte
9%
Immunology and Microbiology
Multiple Sclerosis
72%
Natalizumab
14%
Alertness
14%
Daclizumab
14%
Teriflunomide
14%
Fingolimod
14%
Rituximab
14%
Alemtuzumab
14%
Laquinimod
14%
Inflammatory Disorder
14%
Central Nervous System
14%
Immune Response
14%